Business Wire

SES

22.9.2022 10:45:52 CEST | Business Wire | Press release

Share
SES, ESA and European Commission Partnering to Deliver Satellite Quantum Cryptography System for European Cybersecurity

An SES-led consortium of 20 European companies, with the European Space Agency (ESA) and European Commission support, will design, develop, launch and operate the EAGLE-1 satellite-based end-to-end system for secure Quantum Key Distribution (QKD), enabling in-orbit validation and demonstration of next-generation cyber-security across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005427/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SES, ESA and European Commission Partnering to Deliver Satellite Quantum Cryptography System for European Cybersecurity (Graphic: Business Wire)

The groundbreaking partnership between ESA and an SES-led consortium, with the European Commission support, is advancing Europe to the front of space innovation with satellite-enabled QKD. Together with its European partners, SES will build the first sovereign European end-to-end space-based QKD system, developing and operating a dedicated low earth orbit (LEO) satellite and building a state-of-the-art QKD operations centre in Luxembourg. The project is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.

Using the EAGLE-1 system, ESA and the European Union Member States will achieve the first step to demonstrate and validate QKD technologies from low earth orbit to the ground. The EAGLE-1 project will provide valuable mission data for next generation Quantum Communication Infrastructures (QCIs), contributing for example to the EU plans to deploy a sovereign, autonomous cross-border quantum secure communications networks.

The EAGLE-1 satellite is due to launch in 2024 and will then complete three years of in-orbit mission supported by the European Commission. During this operational phase, the satellite will allow European Union governments and institutions as well as critical business sectors early access to long-distance QKD to path the way towards an EU constellation enabling ultra-secure data transmissions.

To implement the ultra-secure cryptographic key exchange system of EAGLE-1, the consortium will develop the QKD payload, terrestrial optical station, scalable quantum operational networks and key management system to interface with national QCIs.

Josef Aschbacher, ESA Director General, said, “European space innovation has gained strong momentum both from a technology perspective and in terms of commercialisation. It allows us to develop and implement next-generation, future-proof projects in space across critical domains like secure communication, next-generation networks and cybersecurity. Led by ESA, partially financed by the European Commission and implemented by SES, EAGLE-1 is a major step towards making the secure and scalable European Quantum Communications Infrastructure a reality.”

Elodie Viau, Director of Telecommunications and Integrated Applications at ESA, said, “In today’s increasingly interconnected world, keeping information secure is paramount. Robust encryption keys as well as technologies enabling their secure distribution are vital to this endeavour. We are proud to forge this partnership between ESA and a consortium led by SES to create the EAGLE-1 highly secure and autonomous quantum key distribution system. ESA enables the European space industry to succeed by federating industry around large-scale programmes, achieving competitive leaps forward.”

“European security and sovereignty in a future world of quantum computing is critical to the success of Europe and its Member States,” said Steve Collar, CEO of SES. “We are proud to leverage our multi-orbit credentials and our innovative platforms and solutions in partnership with ESA, the European Commission and the Luxembourg Government to advance quantum communications and implement the EAGLE-1 system, which is called to be a cornerstone for the development of secure and sovereign European networks of the future.”

For more information, visit the EAGLE-1 Newsroom

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >

Visit the Media Gallery >

About ESA

The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see www.esa.int

The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners. For more information, please visit our website: https://artes.esa.int/

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005427/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye